No Data
No Data
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development With Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix Executive Acquires Significant Share Volume, Signaling Confidence in Future Growth
Nanobiotix Updates Share Capital and Voting Rights Information
Nanobiotix ADRs Jump on Completed Pancreatic Cancer Treatment Study
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Nanobiotix's NBTXR3 Clinical Advancements: Promising Outcomes and Strategic Expansion Drive Buy Rating